<DOC>
	<DOCNO>NCT00375076</DOCNO>
	<brief_summary>In prospective , randomize , double-blind trial , effect two different dosage LMWH ( 5000 anti-Xa U od sc 10 000 anti-Xa U od sc daily ) marker hemostatic system thrombin generation investigate non-surgical cancer patient investigate .</brief_summary>
	<brief_title>Comparison Two Different Dosages Low-molecular Weight Heparin Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients ( &gt; 18 year ) active cancer least one follow indication thromboprophylaxis LMWH : Immobilization History VTE Acute inflammation Heart failure ( NYHA class III IV ) Respiratory failure Indication LMWH UFH therapeutic dosage Treatment antithrombotics ( vitamin K antagonist , acetylsalicylic acid , clopidogrel ) reason prevention VTE ( e.g . atrial fibrillation , myocardial infarction ) Contraindication treatment LMWH Major surgery within last 4 week ; minor surgery within last week Thrombocytopenia ( &lt; 100.000/Î¼l ) Prolonged prothrombin time Prolonged activate partial thromboplastin time ( aPTT ) History heparininduced thrombocytopenia Bodyweight &lt; 50 kg &gt; 100 kg Renal insufficiency ( creatinine &gt; 2 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>